Move to topTop

TOKYO, JAPAN - May 11, 2018 - Terumo Corporation (TSE: 4543) today announced that it has appointed an associate of MicroVention, Inc., a U.S.-based subsidiary of Terumo, as the fifth "Terumo Fellow." Terumo instituted the Terumo Fellow program to recognize associates who have made outstanding contributions leading to innovation in medical settings, and in the technology, research, and clinical development of the Terumo Group. Terumo created the program and appointed four individuals as Terumo Fellows in 2016.

The new appointed person is Gregory M. Cruise, Ph.D., Senior Director, Materials Development, MicroVention, Inc. His work to develop innovative coils for intracerebral aneurysms has been recognized as having had a major positive impact not only on the MicroVention business, but also on the lives of patients themselves. In addition to this, he has been providing a great value to cancer patients with unique microbeads technologies.

Terumo has established its Global Vision as "Innovating at the Speed of Life," with the aim of achieving further innovation for the benefit of medical professionals and the lives of patients. Terumo will continue to pursue research and development that will produce innovation that benefits healthcare throughout the world.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.